Results: There were 164 men and 46 women in the study group, with a mean age of 63 ± 11 years (range, 31e92 years). Among them, 67 patients (31.9%) received surgical resection and 143 patients (68.1%) received TACE. Patients receiving surgical resection had a significantly larger mean of maximum tumor size (6.8 ± 2.8 vs. 5.8 ± 3.2 cm, P ¼ 0.016), higher ratio of solitary tumor (68.7% vs. 17.5%, P < 0.001), and Child-Pugh class A (97% vs. 85%, P ¼ 0.009) than those with TACE. Patients receiving surgical resection had a significantly higher 1, 3, and 5 year survival rate compared with those treated with TACE (87.4%, 62.8% and 57.3% vs. 58.1%, 29.9% and 16.6%, P < 0.001). Multivariate analysis revealed that AFP level >400 ng/ml [hazard ratio (HR):2.141, 95% CI: 1.091e4.203, P ¼ 0.027], Child B cirrhosis (HR: 4.726, 95% CI: 1.021e21.884, P ¼ 0.047), and TACE (HR:3.391, 95% CI: 1.625e7.076, P ¼ 0.001) were independent risk factors associated with poor prognosis. Conclusions: Our results indicated that surgical resection provided superior survival benefit than TACE to patients with intermediate-stage HCC. This is in part attributable to advances in liver surgery which make the resection of intermediate-stage HCC possible. Surgical resection should be considered first for patients with preserved liver function.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. More than 75% of HCC cases occur in the Far East and Southeast Asia. 1 Only a small proportion of patients have their HCC detected in an early curable stage, thus the worldwide 5-year survival rate of HCC only slightly increased from 5 to 15% over the past two decades. 2 The major causes of unsatisfactory prognosis of HCC include degree of liver function impairment and heterogeneous nature of HCC, which affect treatment outcome. 3 Cumulative evidence also suggests that accurate assessment and staging of HCC, and correct designation of optimal treatments may prolong survival rate of HCC. 4, 5 Among current HCC staging systems, the Barcelona Clinic Liver Cancer (BCLC) classification is the one of most reliable for prognosis prediction at the time of HCC diagnosis. 6, 7 To be categorized as BCLC intermediate-stage, patients are asymptomatic (performance status score, 0) with multinodular tumors but without vascular invasion or extrahepatic spread. The median survival time was 16 months for patients with BCLC intermediatestage HCC. 6 Based on the AASLD guideline, a revised version of the Barcelona Clinic Liver Cancer (BCLC) staging system by the American Association for the Study of Liver Diseases (AASLD), 4, 5 transarterial chemoembolization (TACE) has been recognized as an effective option for those with intermediate stage HCC. 4, 5, 8 Although TACE has been considered a palliative treatment for unresectable HCC, previous meta-analyses indicated that treatment with TACE is associated with a significantly higher 2-year survival rate than those patients receiving conservative management or suboptimal therapies. 
Materials and methods

Patients
A total of 210 newly diagnosed intermediate stage HCC patients, including 67 patients (31.9%) with surgical resection and 143 patients (68.1%) with TACE, were retrospectively enrolled from Ren-Ai Branch, Taipei City Hospital between January 1998 and May 2013. The liver function reserve was assessed by the Child-Turcotte-Pugh (CTP) score. 16 The diagnosis of HCC was histologically confirmed in all patients receiving surgical resection and 87 (60.8%) of patients with TACE treatment. The remaining 56 (39.2%) patients with TACE treatment were confirmed by typical imaging exhibited through arterial enhancement and portal venous washout on multiphasic computed tomography (CT) or magnetic resonance imaging (MRI). 4, 5 (Fig. 1 ). In the weekly multidisciplinary conference, all patients were discussed, and their eligibility for surgical resection or TACE was evaluated based on images, laboratory analyses and medical history. This study protocol was approved by the institutional review board of Taipei City Hospital.
Biochemical and serological testing
The biochemical tests were measured using routine automated methods. The HBsAg and anti-HCV were assayed using commercial kits (General Biological HBsAg RIA, General Biological Cooperation, Taiwan. HCV EIA II. Abbott Laboratories, North Chicago, IL, USA).
Procedure of surgical resection
Indications for surgery were: 1) CTP classification grade of A or B, 2) performance status test was grade 0 or 1, 3) solitary or multiple tumors which were clinically resectable, or 4) the presence of appropriate residual liver volume. 17 Intraoperative ultrasound was routinely performed to determine tumor location and precise definition of tumorevessel relationship. Anatomic segmental resections were performed for potentially curative operation. Additionally, the resection margin was more than 1 cm.
Procedure of TACE
The standardized procedure of TACE was described previously. 18 In brief, TACE procedures were performed in a dedicated angiography suite DFP8000D (Toshiba Medical Systems, Otawara, Japan) with 4Fr J-Curve catheters (Terumo Medical Corporation, Tokyo, Japan) inserted via the right external femoral artery puncture, guided by a matching mandrel (Terumo Medical Corporation, Tokyo). The J-Curve catheter tip was placed in the celiac axis orifice, and one set of digital subtraction angiography was performed. For patients with S5 or S6 tumors which might draw their tumor vessels from superior mesenteric branches, a set of digitallysubtracted superior mesenteric angiography was also performed. If the tumor stains and the supplying vessels were not welldemonstrated by the above angiograms, further superselective angiograms were performed including angiograms of the common hepatic artery, proper hepatic artery, right or left hepatic arteries, and sometimes even the smaller segmental branches. Embolization was performed from the appropriate site, which usually was the proper hepatic artery for multiple bilateral tumors, and the right or left hepatic arteries for unilateral tumors. 
Patient follow-up
After surgical resection or TACE, all patients underwent regular follow-up, including a liver function test, measurement of serum alpha fetoprotein (AFP) levels and abdominal ultrasonography at an interval of 2e3 months. For patients with TACE treatment, the presence of viable tumor was confirmed on multiphasic CT or MRI one to two months after TACE. Thereafter, TACE was repeated in 2e3 month intervals until complete tumor necrosis. When intrahepatic recurrence was suspected, further investigation was carried out using CT or MRI. Patients with recurrence would receive the appropriate treatment options based on clinical decision making.
Statistical analysis
Data were analyzed by chi-square test, Fisher's exact test, Student's t-test and logistic regression where appropriate. Overall survival was measured from the day of HCC diagnosis and when patient survival was confirmed through June 2013. Cumulative survival was calculated according to the KaplaneMeier method. The association of potential risk factors of mortality was determined by univariate and multivariate logistic regression. All tests were two-tailed and a P value of less than 0.05 was considered statistically significant.
Results
Baseline clinical characteristics of the 210 intermediate stage HCC patients are shown in Table 1 . There were 164 men (78.1%) and 46 women (21.9%), with a mean age of 63 ± 11 years (range: 31e92 years). Among them, 67 patients (31.9%) received surgical resection and 143 patients (68.1%) received TACE. There were no significant differences in terms of sex, age, prevalence of HBV/HCV infection and ratio of AFP >400 ng/ml between patients treated with surgical resection and TACE. Compared to patients receiving TACE treatment, patients with surgical resection had a significantly larger mean of maximum tumor size (6.8 ± 2.8 vs. 5.8 ± 3.2 cm, P ¼ 0.016), a higher ratio of tumor number <3 (89.6% vs. 40.6%, P < 0.001), CTP class A cirrhosis (97% vs. 85%, P ¼ 0.009), higher serum albumin level (3.86 ± 0.48 vs. 3.44 ± 0.38 g/dL, P ¼ 0.003), lower serum total bilirubin level (0.92 ± 0.51 vs. 1.25 ± 0.89 mg/dL, P ¼ 0.003), and lower serum AST level (60 ± 53 vs. 93 ± 104 U/L, P ¼ 0.015).
During a median (25e75 percentile) follow-up period of 17 (39e7) months, patients receiving surgical resection had a significantly higher 1, 3, and 5 year survival rate compared with those treated with TACE (87.4%, 62.8% and 57.3% vs. 58.1%, 29.9% and 16.6%, P < 0.001) (Fig. 2) . The median survival time was 70 months in patients receiving surgical resection and 17 months in those with TACE (P < 0.001).
Cox regression analysis for risk factors associated with survival was shown in Table 2 Further subgroup survival analysis was performed for 108 intermediate stage hepatocellular carcinoma patients with CTP class A and a tumor number less than three. Similar to the entire cohort, patients receiving surgical resection had a significantly higher 1, 3, and 5 year survival rate compared with those treated with TACE (89.2%, 65.2% and 58.7% vs. 63%, 41.4% and 18.4%, P < 0.001) (Fig. 3) . The median survival time was 70 months in patients receiving surgical resection and 32 months in those with TACE (P < 0.001).
Discussion
Our results indicated that surgical resection provided superior survival benefit than TACE to patients with intermediate stage HCC, irrespective of CTP class A or B cirrhosis. Surgical resection was identified as an independent factor associated with survival by Cox regression analysis.
According to the BCLC staging system and recommended treatment strategy (AASLD guideline), TACE has been recognized as an effective treatment option for those with intermediate stage HCC. 4, 5 Cumulative meta-analysis of published randomized controlled trials further indicates that patient survival is significantly improved after TACE. 10 However, the 1-year mortality of intermediate stage HCC patients receiving TACE still remains 23, 24 In our study, most patients (97%) who received surgical resection had CTP class A cirrhosis. Similar to previous studies, our results showed that patients with surgical resection had significantly higher long-term survival rates than patients with TACE. In addition, CTP class B cirrhosis was identified as independent risk factors associated with poor prognosis. Taken together, the selection of ideal candidates with preserved liver function for surgical resection should improve long-term survival of intermediate stage HCC. In our study, AFP level >400 ng/ml was a risk factor associated with poor prognosis. Serum AFP level has been recognized as a poor prognostic factor through poor tumor biological behavior, such as tumor multiplicity, poor differentiation and carcinoma cell embolus, as well as moderate/severe cirrhosis. 18 ,25e27 Therefore, incorporation
of AFP level to current HCC staging systems is recommended in evaluating prognosis and subclassification for intermediate stage HCC patients to tailor optimal therapeutic modality. 28 There are several limitations of this study. First, as a retrospective study design, the existence of patient selection bias for surgical resection or TACE should be considered. Second, the standard selection criteria for surgical resection are not well established. In addition, the frequency of TACE administration for individual patients varies in our study, which was influenced by tumor progression and severity of cirrhosis during the follow-up period. Therefore, large cohort studies are required to further evaluate the optimum treatment strategy for intermediate stage HCC patients.
In conclusion, our results indicated that surgical resection provides superior survival benefit than TACE to patients with intermediate stage HCC. Advances in liver surgery make the resection of intermediate stage HCC possible. Surgical resection should be considered first for patients with preserved liver functions. However, standard selection criteria for surgical resection are needed. It is foreseen that surgical resection will play an important role in treatment for intermediate stage HCC, now and into the future.
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